Econ Financial Services Corp Acquires New Position in Biogen Inc. $BIIB

Econ Financial Services Corp acquired a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,946 shares of the biotechnology company’s stock, valued at approximately $694,000.

Other large investors have also bought and sold shares of the company. GoalVest Advisory LLC bought a new stake in shares of Biogen during the fourth quarter valued at approximately $35,000. Elevation Point Wealth Partners LLC purchased a new position in Biogen in the 2nd quarter worth approximately $25,000. Accredited Wealth Management LLC lifted its position in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. Elevation Wealth Partners LLC lifted its position in Biogen by 412.8% in the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 161 shares in the last quarter. Finally, True Wealth Design LLC boosted its stake in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose regimen of SPINRAZA, which could bolster Biogen’s rare‑disease revenue and defend market share in spinal muscular atrophy; the approval was cited as a catalyst for an earlier share pop. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen agreed to buy Apellis for about $5.6B, gaining commercial drugs (EMPAVELI®, SYFOVRE®) and entry into nephrology and ophthalmology — a strategic move to diversify beyond MS and lift long‑term growth expectations. Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings after the news — firms note the approvals and deal are constructive but that execution, MS franchise erosion and competition limit near‑term upside. Spinraza HD approval supports but does not transform outlook
• Negative Sentiment: Market reaction is mixed-to-negative for BIIB: Apellis stock more than doubled on the buyout (market sees strong value in Apellis), while Biogen shares fell as investors weigh the $5.6B cash outlay, premium paid and contingent CVR payments. Apellis Pharma Skyrockets on Biogen Deal
• Negative Sentiment: Integration and financial risk: analysts and commentary flag potential near‑term pressure on cash and the need to execute launches and cross‑sell acquired products; some view the price as a premium that constrains near‑term EPS benefit. Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen Price Performance

Shares of BIIB opened at $183.33 on Wednesday. The firm has a fifty day simple moving average of $186.19 and a two-hundred day simple moving average of $170.98. The firm has a market cap of $26.91 billion, a PE ratio of 20.81, a P/E/G ratio of 1.49 and a beta of 0.15. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the business posted $3.44 EPS. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on BIIB. Morgan Stanley set a $190.00 target price on Biogen in a report on Sunday, February 8th. Wedbush increased their price objective on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Canaccord Genuity Group increased their price objective on Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, February 9th. BMO Capital Markets lifted their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Finally, HC Wainwright boosted their target price on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $205.31.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.